Reactions 1680, p213 - 2 Dec 2017 Tardive dyskinesia: case report A 33-year-old woman developed tardive dyskinesia (TD) during treatment with lurasidone [route not stated]. The woman, who had a history of generalised anxiety disorder, bipolar disorder and post-traumatic stress disorder, presented with the symptoms of irritability, decreased interest, low mood, poor concentration and low energy. She was receiving clonidine, lithium and lorazepam for anxiety treatment. In addition to this, lurasidone 20mg added for bipolar depression. In the subsequent months, lurasidone dose was increased to 60mg at bedtime (HS). She also received benzatropine for the prophylaxis of extrapyramidal symptoms (EPS). Later, she was lost to follow up and stopped the medication for 2 months. Upon her return, she again received lurasidone 40mg HS along with lithium for bipolar depression. She also received clonazepam and benzatropine for anxiety and EPS prophylaxis, respectively. Lithium and benzatropine were stopped because of nausea and double vision. Clonazepam therapy was stopped because of poor response. Then, she received eszopiclone and gabapentin for sleep and anxiety, respectively. Her lurasidone dose was increased to 60mg at bedtime, and 9 weeks after the lurasidone therapy re-initiation, she experienced involuntary tongue movements. Then, lurasidone induced TD was suspected. Subsequently, the woman’s lurasidone therapy was stopped in the following weeks, and her clonazepam therapy was re- initiated. Ten weeks after the lurasidone discontinuation, her TD symptoms disappeared. Author comment: "Here we report a case of lurasidone- induced TD." "In our case, TD symptoms remitted 10 weeks after discontinuation of lurasidone. Clinically this case exemplifies early identification of TD and discontinuation of offending agent as potentially reversing the course of TD." Sinha S, et al. Tardive dyskinesia in the era of second generation antipsychotics: A case report and literature review. CNS Spectrums 21: 98-99 (plus poster), No. 1, 22 Feb 2016. Available from: URL: https://doi.org/10.1017/S1092852915000905 [abstract] - USA 803284802 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera